Cytochrome P450-Mediated Metabolism and CYP Inhibition for the Synthetic Peroxide Antimalarial OZ439.

OZ439 is a potent synthetic ozonide evaluated for the treatment of uncomplicated malaria. The metabolite profile of OZ439 was characterized in vitro using human liver microsomes combined with LC/MS-MS, chemical derivatization, and metabolite synthesis. The primary biotransformations were monohydroxylation at the three distal carbon atoms of the spiroadamantane substructure, with minor contributions from N-oxidation of the morpholine nitrogen and deethylation cleavage of the morpholine ring. Secondary transformations resulted in the formation of dihydroxylation metabolites and metabolites containing both monohydroxylation and morpholine N-oxidation. With the exception of two minor metabolites, none of the other metabolites had appreciable antimalarial activity. Reaction phenotyping indicated that CYP3A4 is the enzyme responsible for the metabolism of OZ439, and it was found to inhibit CYP3A via both direct and mechanism-based inhibition. Elucidation of the metabolic pathways and kinetics will assist with efforts to predict potential metabolic drug-drug interactions and support physiologically based pharmacokinetic (PBPK) modeling.

[1]  David M. Shackleford,et al.  An in vitro toolbox to accelerate anti-malarial drug discovery and development , 2020, Malaria Journal.

[2]  P. Mäser,et al.  Anti-malarial ozonides OZ439 and OZ609 tested at clinically relevant compound exposure parameters in a novel ring-stage survival assay , 2019, Malaria Journal.

[3]  J. McCarthy,et al.  A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers , 2019, Antimicrobial Agents and Chemotherapy.

[4]  J. Simpson,et al.  Ozonide Antimalarial Activity in the Context of Artemisinin-Resistant Malaria. , 2019, Trends in parasitology.

[5]  T. Wells,et al.  The antimalarial pipeline , 2018, Current opinion in pharmacology.

[6]  J. McCarthy,et al.  Model-Informed Drug Development for Malaria Therapeutics , 2017, Annual review of pharmacology and toxicology.

[7]  David M. Shackleford,et al.  Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439). , 2017, Journal of medicinal chemistry.

[8]  J. Burrows,et al.  New developments in anti-malarial target candidate and product profiles , 2017, Malaria Journal.

[9]  J. McCarthy,et al.  Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers , 2016, The Journal of antimicrobial chemotherapy.

[10]  L. Tilley,et al.  Comparison of the Exposure Time Dependence of the Activities of Synthetic Ozonide Antimalarials and Dihydroartemisinin against K13 Wild-Type and Mutant Plasmodium falciparum Strains , 2016, Antimicrobial Agents and Chemotherapy.

[11]  F. Nosten,et al.  Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial , 2016, The Lancet. Infectious diseases.

[12]  Sue J Lee,et al.  Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects , 2014, Antimicrobial Agents and Chemotherapy.

[13]  S. Sharma,et al.  Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  G. S. Walker,et al.  Selective Mechanism-Based Inactivation of CYP3A4 by CYP3cide (PF-04981517) and Its Utility as an In Vitro Tool for Delineating the Relative Roles of CYP3A4 versus CYP3A5 in the Metabolism of Drugs , 2012, Drug Metabolism and Disposition.

[15]  C. Siethoff,et al.  First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials , 2012, British journal of clinical pharmacology.

[16]  A. Gautam,et al.  Pharmacokinetics and Pharmacodynamics of Arterolane Maleate Following Multiple Oral Doses in Adult Patients With P. falciparum Malaria , 2011, Journal of clinical pharmacology.

[17]  Christian Scheurer,et al.  Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria , 2011, Proceedings of the National Academy of Sciences.

[18]  A. Dash,et al.  Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  J. Keiser,et al.  Structure-activity relationship of an ozonide carboxylic acid (OZ78) against Fasciola hepatica. , 2010, Journal of medicinal chemistry.

[20]  Chuang Lu,et al.  The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America , 2009, Drug Metabolism and Disposition.

[21]  A. Ruf,et al.  Characterization of the two major CYP450 metabolites of ozonide (1,2,4-trioxolane) OZ277. , 2008, Bioorganic & medicinal chemistry letters.

[22]  Karthik Venkatakrishnan,et al.  Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.

[23]  J. Chollet,et al.  Effect of functional group polarity on the antimalarial activity of spiro and dispiro-1,2,4-trioxolanes. , 2006, Bioorganic & medicinal chemistry.

[24]  R. Prankerd,et al.  Chemical kinetics and aqueous degradation pathways of a new class of synthetic ozonide antimalarials. , 2006, Journal of pharmaceutical sciences.

[25]  Christian Scheurer,et al.  Identification of an antimalarial synthetic trioxolane drug development candidate , 2004, Nature.

[26]  R. Obach,et al.  Validated assays for human cytochrome P450 activities. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[27]  K. Griesbaum,et al.  Ozonolyses of O‐Alkylated Ketoximes in the Presence of Carbonyl Groups: A Facile Access to Ozonides , 1997 .

[28]  S. Sligar,et al.  Regioselectivity in the cytochromes P-450: control by protein constraints and by chemical reactivities. , 1984, Archives of biochemistry and biophysics.

[29]  R. Silverman.  Mechanism-based enzyme inactivators. , 1995, Methods in enzymology.

[30]  W. L. Noble,et al.  Face selection in the reduction of p,p'-disubstituted 5,7-diphenyl-2-adamantanones and hydrolysis of the corresponding 2-adamantyl tosylates , 1994 .